The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells

Blood

Volumn 108, Issue 10, 2006, Pages 3538-3547

  Aichberger, Karl J ^b   Mayerhofer, Matthias ^b   Vales, Anja ^b   Krauth, Maria Theresa ^b   Gleixner, Karoline V ^b   Bilban, Martin ^b   Esterbauer, Harald ^b   Sonneck, Karoline ^b   Florian, Stefan ^b   Derdak, Sophia ^b   Pickl, Winfried F ^b   Agis, Hermine ^b   Falus, Andras ^b   Sillaber, Christian ^b   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTOCHROME P450; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTIDINE DECARBOXYLASE; IMATINIB; LORATADINE; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE INHIBITOR; TERFENADINE;

ARTICLE; BASOPHIL; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 33751294824     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-028456     Document Type: Article

References (56)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
3. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765-767.
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
5. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003;40:4-10.
6. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18:545-568.
7. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
8. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
9. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myelogenous leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:20-26.
10. Sillaber C, Mayerhofer M, Agis H, et al. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr. 2003;115:485-504.
11. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
12. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.
13. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
14. Denburg JA, Wilson WE, Bienenstock J. Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia. Blood. 1982;60:113-120.
15. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
16. Steegmann JL, Odriozola J, Rodriguez-Salvanes F, et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica. 1999;84:978-987.
17. Hartman WJ, Clark WG, Cyr SD. Histidine decarboxylase activity of basophils from chronic myelogenous leukemic patients: origin of blood histamine. Proc Soc Exp Biol Med. 1961;107:123-125.
18. Valent P, Bettelheim P. The human basophil. Crit Rev Oncol Hematol. 1990;10:327-352.
19. Denburg JA, Wilson WE, Goodacre R, Bienenstock J. Chronic myeloid leukaemia: evidence for basophil differentiation and histamine synthesis from cultured peripheral blood cells. Br J Haematol. 1980;45:13-21.
20. Bettelheim P, Valent P. Radioimmunometric determination of histamine in myeloproliferative syndromes. Wien Klin Wochenschr. 1989;101:706-710.
21. Schneider E, Pollard H, Lepault F, Guy-Grand D, Minkowsky M, Dy M. Histamine-producing cell-stimulating activity: interleukin-3 and granulocyte-macrophage colony-stimulating factor induce de novo synthesis of histidine decarboxylase in hematopoietic progenitor cells. J Immunol. 1987;139:3710-3717.
22. Valent P, Schmidt G, Besemer J, et al. Interleukin-3 is a differentiation factor for human basophils. Blood. 1989;73:1763-1769.
23. Dy M, Machavoine F, Lebel B, Ichikawa A, Gastinel LN, Schneider E. Interleukin-3 promotes histamine synthesis in hematopoietic progenitors by increasing histidine decarboxylase mRNA expression. Biochem Biophys Res Commun. 1993;192:167-173.
24. Bencsath M, Gidali J, Szeberenyi J, Veszely G, Hegyi K, Falus A. Regulation of murine hematopoietic colony formation by histamine. Inflamm Res. 2000;49:S66-S67.
25. Bencsath M, Gidali J, Brandes LJ, Falus A. Murine and human hematopoietic colony formation: a possible regulatory role for intracellular histamine. Acta Biol Hung. 2002;53:299-306.
26. Ohtsu H, Tanaka S, Terui T, et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 2001;502:53-56.
27. Wiener Z, Andrasfalvy M, Pallinger E, et al. Bone marrow-derived mast cell differentiation is strongly reduced in histidine decarboxylase knockout, histamine-free mice. Int Immunol. 2002;14:381-387.
28. Maslinski C. Histamine and its metabolism in mammals, part I: chemistry and formation of histamine. Agents Actions. 1975;5:89-107.
29. Bosma TJ, Kennedy MA, Bodger MP, Hollings PE, Fitzgerald PH. Basophils exhibit rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia. 1988;2:141-143.
30. Bodger MP, Morris CM, Kennedy MA, Bowen JA, Hilton JM, Fitzgerald PH. Basophils (Bsp-1+) derive from the leukemic clone in human myeloid leukemias involving the chromosome breakpoint 9q34. Blood. 1989;73:777-781.
31. Bühring HJ, Simmons PJ, Pudney M, et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood. 1999;94:2343-2356.
32. Bühring HJ, Seiffert M, Giesert C, et al. The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood. 2001;97:3303-3305.
33. Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J Immunol. 1995;154:6548-6555.
34. Brandes LJ, Queen GM, LaBella FS. N, N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE), a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isoenzymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol. 2000;45:298-304.
35. LaBella FS, Brandes LJ. Interaction of histamine and other bioamines with cytochromes P450: implications for cell growth modulation and chemopotentiation by drugs. Sem Cancer Biol. 2000;10:47-53.
36. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
37. Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998;91:3927-3934.
38. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002;100:3767-3775.
39. Valent P, Besemer J, Kishi K, et al. IL-3 promotes basophilic differentiation of KU812 cells through high affinity binding sites. J Immunol. 1990;145:1885-1889.
40. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
41. Cattoretti G, Pileri S, Parravicini C, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993;171:83-98.
42. Krauth MT, Agis H, Aichberger KJ, et al. Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. Hum Pathol. 2006;37:439-447.
43. Agis H, Krauth MT, Mosberger I, et al. Enumeration and characterization of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol. 2006;59:396-402.
44. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752-759.
45. Watanabe T, Yamatodani A, Maeyama K, Wada H. Pharmacology of α-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase. Trends Pharmacol Sci. 1990;11:363-367.
46. Chomczynski P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal Biochem. 1992;201:134-139.
47. Nagai F, Hiyoshi Y, Sugimachi K, Tamura H. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull. 2002;25:383-385.
48. Van Cruchten S, van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 2002;31:214-223.
49. Mamune-Sato R, Yamauchi K, Tanno Y, et al. Functional analysis of alternatively spliced transcripts of the human histidine decarboxylase gene and its expression in human tissues and basophilic leukemia cells. Eur J Biochem. 1992;209:533-539.
50. Dy M, Arnould A, Lemoine FM, Machavoine F, Ziltener H, Schneider E. Hematopoietic progenitors and interleukin-3-dependent cell lines synthesize histamine in response to calcium ionophore. Blood. 1996;87:3161-3169.
51. Brandes LJ, LaBella FS, Glavin GB, et al. Histamine as an intracellular messenger. Biochem Pharmacol. 1990;40:1677-1681.
52. Dy M, Schneider E. Histamine-cytokine connection in immunity and hematopoiesis. Cytokine Growth Factor Rev. 2004;15:393-410.
53. Nicolas JM, Whomsley R, Collart P, Roba J. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999;123:63-79.
54. Holyoake TL, Jiang X, Jorgensen HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 2001;97:720-728.
55. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res. 1998;22:1085-1096.
56. Schneider E, Rolli-Derkinderen M, Arock M, Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. 2002;23:255-263.